B-Xpander\u2122\u00a0Quality Features:<\/h3>\n\n\n\n\n- Production in characterised and certified CHO cell line (for GMP-grade manufacturing)<\/li>\n\n\n\n
- High Bioactivity tested by ELISA\/Cell-based Assays<\/li>\n\n\n\n
- Verified Purity & Homogeneity by SEC<\/li>\n\n\n\n
- Low Endotoxin Levels<\/li>\n\n\n\n
- Batch-to-Batch Consistency<\/li>\n\n\n\n
- Animal-component free Production<\/li>\n\n\n\n
- No cross-linking Reagents necessary<\/li>\n<\/ul>\n\n\n\n
B-Xpander\u2122\u00a0CHO Cell Line:<\/h3>\n\n\n\n
The production of the B-Xpander\u2122 uses a characterised and certified proprietary CHO cell line which has been tested on Master Cell Bank Biosafety and GMP compliance.
<\/p>\n\n\n\n
\n\n\n\nB-Xpander\u2122 \u2013 The Multimeric human CD40L Structure<\/h2>\n\n\n\n![\"\"](\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-469.png\")
FIGURE:<\/strong>\u00a0Structure of the B-Xpander\u2122 or Multimeric human CD40L.<\/figcaption><\/figure>\n\n\n\n\n- B-Xpander\u2122 \/ Multimeric human CD40L is a high activity fusion protein construct in which the human CD40L extracellular domain (aa 116-261) is artificially linked via the collagen domain of ACRP30.<\/li>\n\n\n\n
- The ACRP30headless multimerisation domain sequence from mouse Adiponectin allows the multimerisation (10-12 x trimers) of the construct.<\/li>\n\n\n\n
- This construct very effectively simulates the natural membrane-assisted aggregation of human CD40L\u00a0in vivo<\/em>.<\/li>\n\n\n\n
- MultimericLigands developed by AdipoGen Life Sciences are ideal for\u00a0in vitro<\/em>\u00a0&\u00a0ex vivo<\/em>\u00a0applications.<\/li>\n<\/ul>\n\n\n\n
\n\n\n\nB-Xpander\u2122 \u2013 B Cell Expansion (Proliferation)<\/h2>\n\n\n\n
B-Xpander\u2122 increases proliferation of human primary CD19+ B cells as efficiently as other grades of Multimeric human CD40L. Unlike most recombinant CD40L proteins on the market, AdipoGen’s B-Xpander\u2122 and Multimeric CD40L proteins do not need an enhancer (antibody) to multimerise and to be active.<\/p>\n\n\n\n![\"\"](\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-470-1024x745.png\")
FIGURE:<\/strong>\u00a0Measurement of B cell proliferation.
METHOD:\u00a0<\/strong>Activity of B-Xpander\u2122 and 2 different research grades of Multimeric hCD40L is measured by proliferation of human primary CD19+ B cells. Cells (5 x 104<\/sup>\/well) are grown in RPMI medium, glutamine, 10% FBS, IL-4 (human) (10ng\/ml), IL-21 (human) (10ng\/ml) and different concentrations of B-Xpander\u2122 CD40L (human) (rec.) (Animal-Free) (#AG-40B-0010AF), CD40L (human) (multimeric) (rec.) (CSG; Certified Serum Grade) (#AG-40B-0010CSG), CD40L (human) (multimeric) (rec.) (#AG-40B-0010), or a control protein. Cell proliferation is quantified after 4 days using PMS\/MTS (CellTiter 96\u00ae AQueous One Solution Cell Proliferation Assay, Promega). Cells expanded by 10-fold after 4 days to reach 5 x 105<\/sup>\/well.<\/figcaption><\/figure>\n\n\n\n
\n\n\n\nB-Xpander\u2122 \u2013 B Cell Activation<\/h2>\n\n\n\n\n- The multimeric structure of B-Xpander\u2122 mimics the biological activity of membrane-bound human CD40L.<\/li>\n\n\n\n
- B-Xpander\u2122 is the most potent fusion protein alternative to activate human CD40.<\/li>\n\n\n\n
- Using B-Xpander\u2122, no enhancer (antibody) is required for multimerisation and maximal activity.<\/li>\n\n\n\n
- B-Xpander\u2122 is an efficient B cell activation factor.<\/li>\n<\/ul>\n\n\n\n
![\"\"](\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-471-1024x692.png\")
FIGURE:<\/strong>\u00a0B-Xpander\u2122 (Prod. No. AG-40B-0010AF) induces B cell activation.
METHOD:\u00a0<\/strong>PBL cells were incubated in 96-well plates (2×105 cells\/well in 100\u03bcl RPMI supplemented with 10% FCS) for 24 hours at 37\u00b0C with the indicated concentration of B-Xpander\u2122 CD40L (human) (rec.) (Animal Free) (#AG-40B-0010AF), CD40L (human) (multimeric) (rec.) (#AG-40B-0010) or a trimeric human CD40L as a control. Cells were washed with PBS and stained with 2\u03bcl each CD86-PE and CD19-FITC in 50\u03bcl FACS buffer (PBS, 5% fetal calf serum, 0.02% azide) for 20 min. at 4\u00b0C in the dark. After two washes in FACS buffer, samples were then analysed by flow cytometry.<\/figcaption><\/figure>\n\n\n\n
\n\n\n\nB-Xpander\u2122 \u2013 The Power of B Cell Expansion in Adoptive Cell Therapy<\/h2>\n\n\n\n
Embrace the future of immunotherapy research with Multimeric human CD40L-powered B cell expansion. Backed by rigorous scientific research and development, B-Xpander\u2122, AdipoGen’s cutting-edge Multimeric human CD40L-based B cell expansion tool, represents a major improvement in immunotherapy. During Adoptive Cell Transfer (ACT) immunotherapy, activation and expansion of B cells present with T cells in tumour-infiltrating lymphocytes (TILs) by B-Xpander\u2122 leads to increased proliferation and greater abilities of T cells to fight cancer cells (Arnaud, et al. 2022).<\/p>\n\n\n\n
LIT:<\/strong>\u00a0Sensitive identification of neoantigens and cognate TCRs in human solid tumors: M. Arnaud, et al.; Nat. Biotechnol.\u00a040,<\/strong>\u00a0656 (2022)<\/p>\n\n\n\nAdoptive Cell Therapy (ACT)<\/h3>\n\n\n\n
During ACT, T cells are isolated from a patient’s blood or tumour tissue, expanded and activated ex vivo<\/em>, and then re-infused back into the patient to target and eliminate cancer cells. T cells can be engineered to express chimeric antigen receptors (CARs) or T cell receptors (TCRs) that recognise tumour-specific antigens, or they can be expanded to enrich for tumour-infiltrating lymphocytes (TILs) that have natural tumour-specific reactivity. The patient’s tumour cells can then interact with the enlarged TIL cells to screen effector TIL cells that can kill tumour cells. Recently, it has been observed that B cells are a new key player in the Adoptive Cell Therapy. Higher presence of B cells infiltrated with TILs are associated with better TIL expansion and activation. B cells stimulated and amplified with B-Xpander\u2122 and loaded with tumour-specific antigen improve tumour-specific TILs.
<\/p>\n\n\n\n![\"\"](\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-472-1024x465.png\")
<\/a>FIGURE:<\/strong>\u00a0ACT workflow for TIL expansion.<\/figcaption><\/figure>\n\n\n\n
\n\n\n\nB-Xpander\u2122 and Multimeric human CD40L Grades for your experiments:<\/h2>\n\n\n\nProduct Name<\/strong><\/th>PID<\/strong><\/th>Protein Construct<\/strong><\/th><\/tr><\/thead><\/table><\/figure>\n\n\n\nB-Xpander\u2122<\/h3>\n\n\n\nB-Xpander\u2122 CD40L (human) (rec.) (Animal Free)<\/strong><\/td>AG-40B-0010AF<\/a><\/td> \u2022 Produced using animal component-free medium in characterised and certified CHO cells
\u2022 GMP-like production
\u2022 Ex vivo<\/em> B Cell Expansion for Cell Therapy<\/td><\/tr>B-Xpander\u2122 CD40L (human) (rec.) (GMP-Grade)<\/strong><\/td>Custom
Please Inquire<\/td> \u2022 GMP-Production outsourced to CRO
\u2022 Ex vivo<\/em> B Cell Expansion for Cell Therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\nOther Research Grades<\/h3>\n\n\n\nCD40L (human) (multimeric) (rec.)<\/strong><\/td>AG-40B-0010<\/a><\/td> \u2022 Produced using standard serum\/medium in CHO cells
\u2022 Ex vivo<\/em> B Cell Expansion for Research Use<\/td><\/tr>CD40L (human) (multimeric) (rec.) (Certified Serum Grade)<\/strong><\/td>AG-40B-0010CSG<\/a><\/td> \u2022 Produced using certified serum\/medium in CHO cells for traceability
\u2022 Ex vivo<\/em> B Cell Expansion for Cell Therapy and Research Use<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
B-Xpander\u2122\u00a0CHO Cell Line:<\/h3>\n\n\n\n
The production of the B-Xpander\u2122 uses a characterised and certified proprietary CHO cell line which has been tested on Master Cell Bank Biosafety and GMP compliance.
<\/p>\n\n\n\n
\n\n\n\n
B-Xpander\u2122 \u2013 The Multimeric human CD40L Structure<\/h2>\n\n\n\nFIGURE:<\/strong>\u00a0Structure of the B-Xpander\u2122 or Multimeric human CD40L.<\/figcaption><\/figure>\n\n\n\n\n- B-Xpander\u2122 \/ Multimeric human CD40L is a high activity fusion protein construct in which the human CD40L extracellular domain (aa 116-261) is artificially linked via the collagen domain of ACRP30.<\/li>\n\n\n\n
- The ACRP30headless multimerisation domain sequence from mouse Adiponectin allows the multimerisation (10-12 x trimers) of the construct.<\/li>\n\n\n\n
- This construct very effectively simulates the natural membrane-assisted aggregation of human CD40L\u00a0in vivo<\/em>.<\/li>\n\n\n\n
- MultimericLigands developed by AdipoGen Life Sciences are ideal for\u00a0in vitro<\/em>\u00a0&\u00a0ex vivo<\/em>\u00a0applications.<\/li>\n<\/ul>\n\n\n\n
\n\n\n\nB-Xpander\u2122 \u2013 B Cell Expansion (Proliferation)<\/h2>\n\n\n\n
B-Xpander\u2122 increases proliferation of human primary CD19+ B cells as efficiently as other grades of Multimeric human CD40L. Unlike most recombinant CD40L proteins on the market, AdipoGen’s B-Xpander\u2122 and Multimeric CD40L proteins do not need an enhancer (antibody) to multimerise and to be active.<\/p>\n\n\n\nFIGURE:<\/strong>\u00a0Measurement of B cell proliferation.
METHOD:\u00a0<\/strong>Activity of B-Xpander\u2122 and 2 different research grades of Multimeric hCD40L is measured by proliferation of human primary CD19+ B cells. Cells (5 x 104<\/sup>\/well) are grown in RPMI medium, glutamine, 10% FBS, IL-4 (human) (10ng\/ml), IL-21 (human) (10ng\/ml) and different concentrations of B-Xpander\u2122 CD40L (human) (rec.) (Animal-Free) (#AG-40B-0010AF), CD40L (human) (multimeric) (rec.) (CSG; Certified Serum Grade) (#AG-40B-0010CSG), CD40L (human) (multimeric) (rec.) (#AG-40B-0010), or a control protein. Cell proliferation is quantified after 4 days using PMS\/MTS (CellTiter 96\u00ae AQueous One Solution Cell Proliferation Assay, Promega). Cells expanded by 10-fold after 4 days to reach 5 x 105<\/sup>\/well.<\/figcaption><\/figure>\n\n\n\n
\n\n\n\nB-Xpander\u2122 \u2013 B Cell Activation<\/h2>\n\n\n\n\n- The multimeric structure of B-Xpander\u2122 mimics the biological activity of membrane-bound human CD40L.<\/li>\n\n\n\n
- B-Xpander\u2122 is the most potent fusion protein alternative to activate human CD40.<\/li>\n\n\n\n
- Using B-Xpander\u2122, no enhancer (antibody) is required for multimerisation and maximal activity.<\/li>\n\n\n\n
- B-Xpander\u2122 is an efficient B cell activation factor.<\/li>\n<\/ul>\n\n\n\n
FIGURE:<\/strong>\u00a0B-Xpander\u2122 (Prod. No. AG-40B-0010AF) induces B cell activation.
METHOD:\u00a0<\/strong>PBL cells were incubated in 96-well plates (2×105 cells\/well in 100\u03bcl RPMI supplemented with 10% FCS) for 24 hours at 37\u00b0C with the indicated concentration of B-Xpander\u2122 CD40L (human) (rec.) (Animal Free) (#AG-40B-0010AF), CD40L (human) (multimeric) (rec.) (#AG-40B-0010) or a trimeric human CD40L as a control. Cells were washed with PBS and stained with 2\u03bcl each CD86-PE and CD19-FITC in 50\u03bcl FACS buffer (PBS, 5% fetal calf serum, 0.02% azide) for 20 min. at 4\u00b0C in the dark. After two washes in FACS buffer, samples were then analysed by flow cytometry.<\/figcaption><\/figure>\n\n\n\n
\n\n\n\nB-Xpander\u2122 \u2013 The Power of B Cell Expansion in Adoptive Cell Therapy<\/h2>\n\n\n\n
Embrace the future of immunotherapy research with Multimeric human CD40L-powered B cell expansion. Backed by rigorous scientific research and development, B-Xpander\u2122, AdipoGen’s cutting-edge Multimeric human CD40L-based B cell expansion tool, represents a major improvement in immunotherapy. During Adoptive Cell Transfer (ACT) immunotherapy, activation and expansion of B cells present with T cells in tumour-infiltrating lymphocytes (TILs) by B-Xpander\u2122 leads to increased proliferation and greater abilities of T cells to fight cancer cells (Arnaud, et al. 2022).<\/p>\n\n\n\n
LIT:<\/strong>\u00a0Sensitive identification of neoantigens and cognate TCRs in human solid tumors: M. Arnaud, et al.; Nat. Biotechnol.\u00a040,<\/strong>\u00a0656 (2022)<\/p>\n\n\n\nAdoptive Cell Therapy (ACT)<\/h3>\n\n\n\n
During ACT, T cells are isolated from a patient’s blood or tumour tissue, expanded and activated ex vivo<\/em>, and then re-infused back into the patient to target and eliminate cancer cells. T cells can be engineered to express chimeric antigen receptors (CARs) or T cell receptors (TCRs) that recognise tumour-specific antigens, or they can be expanded to enrich for tumour-infiltrating lymphocytes (TILs) that have natural tumour-specific reactivity. The patient’s tumour cells can then interact with the enlarged TIL cells to screen effector TIL cells that can kill tumour cells. Recently, it has been observed that B cells are a new key player in the Adoptive Cell Therapy. Higher presence of B cells infiltrated with TILs are associated with better TIL expansion and activation. B cells stimulated and amplified with B-Xpander\u2122 and loaded with tumour-specific antigen improve tumour-specific TILs.
<\/p>\n\n\n\n<\/a>FIGURE:<\/strong>\u00a0ACT workflow for TIL expansion.<\/figcaption><\/figure>\n\n\n\n
\n\n\n\nB-Xpander\u2122 and Multimeric human CD40L Grades for your experiments:<\/h2>\n\n\n\nProduct Name<\/strong><\/th>PID<\/strong><\/th>Protein Construct<\/strong><\/th><\/tr><\/thead><\/table><\/figure>\n\n\n\nB-Xpander\u2122<\/h3>\n\n\n\nB-Xpander\u2122 CD40L (human) (rec.) (Animal Free)<\/strong><\/td>AG-40B-0010AF<\/a><\/td> \u2022 Produced using animal component-free medium in characterised and certified CHO cells
\u2022 GMP-like production
\u2022 Ex vivo<\/em> B Cell Expansion for Cell Therapy<\/td><\/tr>B-Xpander\u2122 CD40L (human) (rec.) (GMP-Grade)<\/strong><\/td>Custom
Please Inquire<\/td> \u2022 GMP-Production outsourced to CRO
\u2022 Ex vivo<\/em> B Cell Expansion for Cell Therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\nOther Research Grades<\/h3>\n\n\n\nCD40L (human) (multimeric) (rec.)<\/strong><\/td>AG-40B-0010<\/a><\/td> \u2022 Produced using standard serum\/medium in CHO cells
\u2022 Ex vivo<\/em> B Cell Expansion for Research Use<\/td><\/tr>CD40L (human) (multimeric) (rec.) (Certified Serum Grade)<\/strong><\/td>AG-40B-0010CSG<\/a><\/td> \u2022 Produced using certified serum\/medium in CHO cells for traceability
\u2022 Ex vivo<\/em> B Cell Expansion for Cell Therapy and Research Use<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
- \n
- B-Xpander\u2122 \/ Multimeric human CD40L is a high activity fusion protein construct in which the human CD40L extracellular domain (aa 116-261) is artificially linked via the collagen domain of ACRP30.<\/li>\n\n\n\n
- The ACRP30headless multimerisation domain sequence from mouse Adiponectin allows the multimerisation (10-12 x trimers) of the construct.<\/li>\n\n\n\n
- This construct very effectively simulates the natural membrane-assisted aggregation of human CD40L\u00a0in vivo<\/em>.<\/li>\n\n\n\n
- MultimericLigands developed by AdipoGen Life Sciences are ideal for\u00a0in vitro<\/em>\u00a0&\u00a0ex vivo<\/em>\u00a0applications.<\/li>\n<\/ul>\n\n\n\n
\n\n\n\nB-Xpander\u2122 \u2013 B Cell Expansion (Proliferation)<\/h2>\n\n\n\n
B-Xpander\u2122 increases proliferation of human primary CD19+ B cells as efficiently as other grades of Multimeric human CD40L. Unlike most recombinant CD40L proteins on the market, AdipoGen’s B-Xpander\u2122 and Multimeric CD40L proteins do not need an enhancer (antibody) to multimerise and to be active.<\/p>\n\n\n\n
FIGURE:<\/strong>\u00a0Measurement of B cell proliferation.
METHOD:\u00a0<\/strong>Activity of B-Xpander\u2122 and 2 different research grades of Multimeric hCD40L is measured by proliferation of human primary CD19+ B cells. Cells (5 x 104<\/sup>\/well) are grown in RPMI medium, glutamine, 10% FBS, IL-4 (human) (10ng\/ml), IL-21 (human) (10ng\/ml) and different concentrations of B-Xpander\u2122 CD40L (human) (rec.) (Animal-Free) (#AG-40B-0010AF), CD40L (human) (multimeric) (rec.) (CSG; Certified Serum Grade) (#AG-40B-0010CSG), CD40L (human) (multimeric) (rec.) (#AG-40B-0010), or a control protein. Cell proliferation is quantified after 4 days using PMS\/MTS (CellTiter 96\u00ae AQueous One Solution Cell Proliferation Assay, Promega). Cells expanded by 10-fold after 4 days to reach 5 x 105<\/sup>\/well.<\/figcaption><\/figure>\n\n\n\n
\n\n\n\nB-Xpander\u2122 \u2013 B Cell Activation<\/h2>\n\n\n\n
- \n
- The multimeric structure of B-Xpander\u2122 mimics the biological activity of membrane-bound human CD40L.<\/li>\n\n\n\n
- B-Xpander\u2122 is the most potent fusion protein alternative to activate human CD40.<\/li>\n\n\n\n
- Using B-Xpander\u2122, no enhancer (antibody) is required for multimerisation and maximal activity.<\/li>\n\n\n\n
- B-Xpander\u2122 is an efficient B cell activation factor.<\/li>\n<\/ul>\n\n\n\n
FIGURE:<\/strong>\u00a0B-Xpander\u2122 (Prod. No. AG-40B-0010AF) induces B cell activation.
METHOD:\u00a0<\/strong>PBL cells were incubated in 96-well plates (2×105 cells\/well in 100\u03bcl RPMI supplemented with 10% FCS) for 24 hours at 37\u00b0C with the indicated concentration of B-Xpander\u2122 CD40L (human) (rec.) (Animal Free) (#AG-40B-0010AF), CD40L (human) (multimeric) (rec.) (#AG-40B-0010) or a trimeric human CD40L as a control. Cells were washed with PBS and stained with 2\u03bcl each CD86-PE and CD19-FITC in 50\u03bcl FACS buffer (PBS, 5% fetal calf serum, 0.02% azide) for 20 min. at 4\u00b0C in the dark. After two washes in FACS buffer, samples were then analysed by flow cytometry.<\/figcaption><\/figure>\n\n\n\n
\n\n\n\nB-Xpander\u2122 \u2013 The Power of B Cell Expansion in Adoptive Cell Therapy<\/h2>\n\n\n\n
Embrace the future of immunotherapy research with Multimeric human CD40L-powered B cell expansion. Backed by rigorous scientific research and development, B-Xpander\u2122, AdipoGen’s cutting-edge Multimeric human CD40L-based B cell expansion tool, represents a major improvement in immunotherapy. During Adoptive Cell Transfer (ACT) immunotherapy, activation and expansion of B cells present with T cells in tumour-infiltrating lymphocytes (TILs) by B-Xpander\u2122 leads to increased proliferation and greater abilities of T cells to fight cancer cells (Arnaud, et al. 2022).<\/p>\n\n\n\n
LIT:<\/strong>\u00a0Sensitive identification of neoantigens and cognate TCRs in human solid tumors: M. Arnaud, et al.; Nat. Biotechnol.\u00a040,<\/strong>\u00a0656 (2022)<\/p>\n\n\n\n
Adoptive Cell Therapy (ACT)<\/h3>\n\n\n\n
During ACT, T cells are isolated from a patient’s blood or tumour tissue, expanded and activated ex vivo<\/em>, and then re-infused back into the patient to target and eliminate cancer cells. T cells can be engineered to express chimeric antigen receptors (CARs) or T cell receptors (TCRs) that recognise tumour-specific antigens, or they can be expanded to enrich for tumour-infiltrating lymphocytes (TILs) that have natural tumour-specific reactivity. The patient’s tumour cells can then interact with the enlarged TIL cells to screen effector TIL cells that can kill tumour cells. Recently, it has been observed that B cells are a new key player in the Adoptive Cell Therapy. Higher presence of B cells infiltrated with TILs are associated with better TIL expansion and activation. B cells stimulated and amplified with B-Xpander\u2122 and loaded with tumour-specific antigen improve tumour-specific TILs.
<\/p>\n\n\n\n<\/a>FIGURE:<\/strong>\u00a0ACT workflow for TIL expansion.<\/figcaption><\/figure>\n\n\n\n
\n\n\n\nB-Xpander\u2122 and Multimeric human CD40L Grades for your experiments:<\/h2>\n\n\n\n
Product Name<\/strong><\/th> PID<\/strong><\/th> Protein Construct<\/strong><\/th><\/tr><\/thead><\/table><\/figure>\n\n\n\n B-Xpander\u2122<\/h3>\n\n\n\n
B-Xpander\u2122 CD40L (human) (rec.) (Animal Free)<\/strong><\/td> AG-40B-0010AF<\/a><\/td> \u2022 Produced using animal component-free medium in characterised and certified CHO cells
\u2022 GMP-like production
\u2022 Ex vivo<\/em> B Cell Expansion for Cell Therapy<\/td><\/tr>B-Xpander\u2122 CD40L (human) (rec.) (GMP-Grade)<\/strong><\/td> Custom
Please Inquire<\/td>\u2022 GMP-Production outsourced to CRO
\u2022 Ex vivo<\/em> B Cell Expansion for Cell Therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\nOther Research Grades<\/h3>\n\n\n\n
CD40L (human) (multimeric) (rec.)<\/strong><\/td> AG-40B-0010<\/a><\/td> \u2022 Produced using standard serum\/medium in CHO cells
\u2022 Ex vivo<\/em> B Cell Expansion for Research Use<\/td><\/tr>CD40L (human) (multimeric) (rec.) (Certified Serum Grade)<\/strong><\/td> AG-40B-0010CSG<\/a><\/td> \u2022 Produced using certified serum\/medium in CHO cells for traceability
\u2022 Ex vivo<\/em> B Cell Expansion for Cell Therapy and Research Use<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
- MultimericLigands developed by AdipoGen Life Sciences are ideal for\u00a0in vitro<\/em>\u00a0&\u00a0ex vivo<\/em>\u00a0applications.<\/li>\n<\/ul>\n\n\n\n
![\"\"](\"https:\/\/www.caltagmedsystems.co.uk\/information\/wp-content\/uploads\/image-472.png\")
<\/a>